Evidence map›Paper›PMID 36680164›Full record

ArticleViruses2022

Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice.

Aruni Jha, Melanie Doyle-Eisele, David Revelli, Trevor Carnelley, Douglas Barker, Shantha Kodihalli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Aruni JhaEmergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Melanie Doyle-EiseleLovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.
David RevelliLovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.
Trevor CarnelleyEmergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Douglas BarkerEmergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Shantha KodihalliEmergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Emergent BioSolutions (Canada) · CABiomedical Research Institute · USLovelace Respiratory Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC

Indexed as

COVID-19AnimalsAntibodiesHumansMicePandemicsRNA, ViralSARS-CoV-2AntibodiesRNA, ViralCOVID-19mouse modelpharmacodynamicspharmacokinetics

Identifiers

PMID36680164
PMCPMC9860936
OpenAlexW4313472389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.